CC 8490

Drug Profile

CC 8490

Latest Information Update: 07 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; National Cancer Institute (USA)
  • Class Antineoplastics; Benzopyrans
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 08 Jun 2006 This compound is still in active development
  • 04 Dec 2003 A clinical study has been added to the pharmacokinetics section ,
  • 29 Oct 2003 Celgene has initiated enrolment in a phase I/II trial for glioblastoma in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top